2013年ESC稳定性冠状动脉疾病管理指南

2013-10-12 DXY DXY

Guidelines summarize and evaluate all evidence available, at the time of the writing process, on a particular issue with the aim of assisting physicians in selecting the best management strategies for

Guidelines summarize and evaluate all evidence available, at the time of the writing process, on a particular issue with the aim of assisting physicians in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means.

Guidelines are not substitutes but are complements for textbooks, and cover the ESC Core Curriculum topics. Guidelines and recommendations should help physicians to make decisions in their daily practice: however, the final decisions concerning an individual patient must be made by the responsible physician(s).

A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user.

Download

2013 ESC guidelines on the management of stable coronary artery disease .European Heart Journal.2013 August 30 doi:10.1093/eurheartj/eht296.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1893823, encodeId=d0b91893823da, content=<a href='/topic/show?id=33a6e0716f1' target=_blank style='color:#2F92EE;'>#疾病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70716, encryptionId=33a6e0716f1, topicName=疾病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Mon Jun 23 03:20:00 CST 2014, time=2014-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900419, encodeId=24a819004192d, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Nov 17 05:20:00 CST 2013, time=2013-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936260, encodeId=34e819362608e, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sat Nov 16 08:20:00 CST 2013, time=2013-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252858, encodeId=639f125285855, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Oct 14 07:20:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625299, encodeId=589f162529957, content=<a href='/topic/show?id=ce70e5302f2' target=_blank style='color:#2F92EE;'>#稳定性冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75302, encryptionId=ce70e5302f2, topicName=稳定性冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8220733002, createdName=liuhuangbo, createdTime=Mon Oct 14 07:20:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1893823, encodeId=d0b91893823da, content=<a href='/topic/show?id=33a6e0716f1' target=_blank style='color:#2F92EE;'>#疾病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70716, encryptionId=33a6e0716f1, topicName=疾病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Mon Jun 23 03:20:00 CST 2014, time=2014-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900419, encodeId=24a819004192d, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Nov 17 05:20:00 CST 2013, time=2013-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936260, encodeId=34e819362608e, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sat Nov 16 08:20:00 CST 2013, time=2013-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252858, encodeId=639f125285855, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Oct 14 07:20:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625299, encodeId=589f162529957, content=<a href='/topic/show?id=ce70e5302f2' target=_blank style='color:#2F92EE;'>#稳定性冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75302, encryptionId=ce70e5302f2, topicName=稳定性冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8220733002, createdName=liuhuangbo, createdTime=Mon Oct 14 07:20:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1893823, encodeId=d0b91893823da, content=<a href='/topic/show?id=33a6e0716f1' target=_blank style='color:#2F92EE;'>#疾病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70716, encryptionId=33a6e0716f1, topicName=疾病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Mon Jun 23 03:20:00 CST 2014, time=2014-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900419, encodeId=24a819004192d, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Nov 17 05:20:00 CST 2013, time=2013-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936260, encodeId=34e819362608e, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sat Nov 16 08:20:00 CST 2013, time=2013-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252858, encodeId=639f125285855, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Oct 14 07:20:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625299, encodeId=589f162529957, content=<a href='/topic/show?id=ce70e5302f2' target=_blank style='color:#2F92EE;'>#稳定性冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75302, encryptionId=ce70e5302f2, topicName=稳定性冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8220733002, createdName=liuhuangbo, createdTime=Mon Oct 14 07:20:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1893823, encodeId=d0b91893823da, content=<a href='/topic/show?id=33a6e0716f1' target=_blank style='color:#2F92EE;'>#疾病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70716, encryptionId=33a6e0716f1, topicName=疾病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Mon Jun 23 03:20:00 CST 2014, time=2014-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900419, encodeId=24a819004192d, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Nov 17 05:20:00 CST 2013, time=2013-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936260, encodeId=34e819362608e, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sat Nov 16 08:20:00 CST 2013, time=2013-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252858, encodeId=639f125285855, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Oct 14 07:20:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625299, encodeId=589f162529957, content=<a href='/topic/show?id=ce70e5302f2' target=_blank style='color:#2F92EE;'>#稳定性冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75302, encryptionId=ce70e5302f2, topicName=稳定性冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8220733002, createdName=liuhuangbo, createdTime=Mon Oct 14 07:20:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1893823, encodeId=d0b91893823da, content=<a href='/topic/show?id=33a6e0716f1' target=_blank style='color:#2F92EE;'>#疾病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70716, encryptionId=33a6e0716f1, topicName=疾病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Mon Jun 23 03:20:00 CST 2014, time=2014-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900419, encodeId=24a819004192d, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Nov 17 05:20:00 CST 2013, time=2013-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936260, encodeId=34e819362608e, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sat Nov 16 08:20:00 CST 2013, time=2013-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252858, encodeId=639f125285855, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Oct 14 07:20:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625299, encodeId=589f162529957, content=<a href='/topic/show?id=ce70e5302f2' target=_blank style='color:#2F92EE;'>#稳定性冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75302, encryptionId=ce70e5302f2, topicName=稳定性冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8220733002, createdName=liuhuangbo, createdTime=Mon Oct 14 07:20:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]

相关资讯

EHJ:他汀均可改善ACS预后

近日,在2013年欧洲心脏病学会年会上,有西班牙学者发表研究表明,即使ACS患者基线LDL-C水平不高,他汀治疗仍可获得明显的中期益处,相关论文发表在欧洲心脏杂志(EuroPean Heart Journal)上。 该研究为一单中心前瞻性观察性研究,为期16个月,观察对象为该中心出院诊断为ACS所有连续患者。患者的LDL-C水平按ESC指南分类(<70 

ESC 2013:LDL-C和动脉壁弹性指标间的相关性

近日,在2013年欧洲心脏病学会年会上,来自波兰的学者发表了针对LDL-C与动脉壁弹性指标相关性进行了研究,研究发现,LDL胆固醇和小动脉弹性指数(C2)间呈负性相关。相关论文发表在在欧洲心脏病学杂志(European Heart Journal)(2013)34(摘要补充),766。

EHJ:植物固醇可影响行降脂治疗患者的血脂水平

近日,在2013年欧洲心脏病学会年会上,来自巴西的学者发表了一项研究结果,研究发现阿托伐他汀可增加肠道固醇的吸收,而依泽替米贝可增加内源性胆固醇的合成。在调脂治疗中加用植物固醇对于血脂及非胆固醇类的固醇效果甚微。长半衰期的大剂量强效他汀类药物合用,如阿托伐他汀与依泽替米贝,可对血脂水平产生更大的益处,同时可降低胆固醇合成及植物固醇血症的发生,尤其当加用植物固醇时。相关论文发表在在欧洲心脏病

ESC 2013:DPP-4抑制剂类糖尿病药物未增加心血管风险

近日,在欧洲心脏协会(ESC)年度会议上,研究人员详细陈述了过去两年针对16492例服用Onglyza和5380例服用Nesina的糖尿病患者的心血管风险研究结果。总体上讲,两项研究表明用于治疗2型糖尿病的二肽基肽酶-4(DPP-4)抑制剂类药物不会导致心脏病发作,但可能会因心脏不能充分泵血,引发心衰。同时,布利甘-妇女医院研究人员称心衰只是个例,还需进一步研究确认。因此,阿斯利康和百时美施贵宝宣

ESC 2013:稳定性冠状动脉疾病指南

2013年9月1日,由Gilles Montalescot及UdoSechtem领导的工作小组在欧洲心脏病学会年会(ESC2013)上公布了最新的稳定性冠状动脉疾病指南。【全文阅读】本次更新的主要内容为:1.自2006年稳定性心绞痛管理与治疗指南出台之后,稳定性冠状动脉疾病(SCAD)的概念已经发生了变革,其范围更加广泛,除以冠状动脉血栓形成为主要临床表现的急性冠脉综合征外,很多CAD均属于SCA

ESC 2013:英国心血管疾病一级预防中血压和血脂的管理:EURIKA研究结果

在2013年欧洲心脏病学会年会上,来自英国的学者发表了针对目前英国与现有指南有关的一级预防中高血压和血脂异常的处理研究结果。